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Abstract 60 
61 
Objectives. Endometrial carcinoma (EC) is the most common gynecological cancer in the Western 62 
World. Treatment options are limited for advanced and recurrent disease. Therefore, new treatment 63 
options are necessary. Inhibition of the PI3K/AKT/mTOR and/or the Ras/Raf/MEK pathways are 64 
suggested to be clinically relevant. However, the knowledge about the effect of combination targeted 65 
therapy in EC is limited. The aim of this study was to investigate the effect of these therapies on 66 
primary endometrioid EC cell cultures in vitro and in vivo.  67 
Methods. Primary microsatellite instable endometrioid EC cell cultures were incubated with 68 
Temsirolimus (mTORC1 inhibitor), NVP-BKM120 (pan-PI3K inhibitor), NVP-BEZ235 (pan-PI3K/mTOR 69 
inhibitor), or AZD6244 (MEK1/2 inhibitor) as single treatment. In vitro, the effect of NVP-BEZ235 with 70 
or without AZD6244 was determined for cell viability, cell cycle arrest, apoptosis induction, and cell 71 
signaling. In vivo, the effect of NVP-BEZ35 was investigated for 2 subcutaneous xenograft models of 72 
the corresponding primary cultures.  73 
Results. NVP-BEZ235 was the most potent PI3K/AKT/mTOR pathway inhibitor. NVP-BEZ235 and 74 
AZD6244 reduced cell viability and induced cell cycle arrest and apoptosis, by reduction of p-AKT, p-75 
S6, and p-ERK levels. Combination treatment showed a synergistic effect. In vivo, NVP-BEZ235 76 
reduced tumor growth and inhibited p-S6 expression. The effects of the compounds were independent 77 
of the mutation profile of the cell cultures used. 78 
Conclusions. A synergistic antitumor effect was shown for NVP-BEZ235 and AZD6244 in primary 79 
endometrioid EC cells in vitro. In addition, NVP-BEZ235 induced reduction of tumor growth in vivo. 80 
Therefore, targeted therapies seems a promising treatment strategy for EC. 81 
82 
Highlights 83 
84 
- NVP-BEZ235 (dual pan-PI3K/mTOR inhibitor) is the most potent PI3K/AKT/mTOR pathway 85 
inhibitor for primary endometrioid endometrial carcinoma cell cultures 86 
- NVP-BEZ235 could reduce tumor growth in xenograft models based on primary endometrioid 87 
endometrial carcinoma cell cultures 88 
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- Combination treatment with NVP-BEZ235 (dual pan-PI3K/mTOR inhibitor) and AZD6244 89 
(MEK inhibitor) shows a synergistic antitumor effect in vitro 90 
 91 
Keywords 92 
 93 
Endometrioid endometrial cancer; primary cell culture; targeted therapy; NVP-BEZ235; AZD6244 94 
 95 
Introduction 96 
 97 
Endometrial cancer is the most common gynecologic malignancy in the Western World and the fourth 98 
most common cancer in women after breast, lung, and colorectal cancers. Since 2008, the incidence 99 
of endometrial cancer has increased by 21% and the mortality rate per 100.000 cases has increased 100 
by more than 100% during the past 20 years[1, 2]. Endometrial carcinoma (EC) is the most common 101 
endometrial cancer subtype. Endometrioid EC (type I) accounts for 85% of EC cases and is 102 
associated with good prognosis. Only 15-20% of the cases show recurrences. In contrast, non-103 
endometrioid EC (type II), like serous and clear cell carcinoma, are aggressive tumors and account for 104 
more than 50% of the recurrences[3]. Patients with advanced or recurrent disease have a poor median 105 
survival, since conventional cytotoxic and radiation therapy are not effective at this stage[4-6]. 106 
Therefore, new treatment options are necessary.   107 
Advances in the understanding of tumor biology have established the critical role of targeted therapy 108 
as treatment options for cancer. In addition, an increasing number of preclinical studies suggest that 109 
the combination of targeted agents is a more promising strategy compared to single agent treatment, 110 
due to feedback loops and cross-talk between signaling pathways. 111 
The phosphatidylinositol 3-kinase enzyme/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) 112 
and Ras/Raf/MEK pathways play a critical role in cell proliferation, survival, differentiation, metabolism 113 
and motility in response to extracellular cues. Within the PI3K/AKT/mTOR pathway there are feedback 114 
loops present. mTOR can increase p70S6K, which in turn phosphorylates and inhibits insulin receptor 115 
substrate 1, a protein upstream of PI3K/AKT. Therefore, mTOR inhibition can lead to activation of the 116 
PI3K/AKT pathway[7]. In addition, the Ras/Raf/MEK pathway cross-activates and cross-inhibits 117 
PI3K/mTORC1 signaling by regulating PI3K, tuberous sclerosis complex 2, and mTORC1[8]. Both 118 
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pathways are commonly deregulated in EC. Therefore, inhibition of both pathways could be a potential 119 
new treatment strategy for EC.  120 
Many valuable inhibitors targeting one protein (single inhibitors) or two proteins at the same time (dual 121 
inhibitors) in these pathways have been recently developed. Temsirolimus (CCI-779) and Everolimus, 122 
both mTORC1 inhibitors, showed clinical activity in recurrent and metastatic EC patients[9, 10]. 123 
However, no correlation between the mutation profile of the primary tumor and response was 124 
determined[11]. NVP-BKM120 is a pan-PI3K inhibitor, which showed antitumor activity in a variety of 125 
tumor cell lines and xenograft models of cancers with and without aberrant PI3K pathway activation, 126 
including primary human EC xenograft models[12, 13]. In addition, phase I clinical studies showed that 127 
NVP-BKM120 is well tolerated in patients[14, 15]. NVP-BEZ235 is a pan-PI3K/mTOR inhibitor, which 128 
induces anticancer effects in several human cancer cell lines and xenograft models, such as models 129 
based on commercial endometrioid EC cell lines[16, 17]. In addition, this inhibitor was the first 130 
PI3K/mTOR dual inhibitor to enter clinical trials[18]. AZD6244 (ARRY-142886) is a potent and 131 
selective inhibitor of MEK1/2 kinases[19]. It is currently in phase II clinical development as a single 132 
agent, including recurrent and persistent EC, or as a combination treatment[20-22]. Preclinical and 133 
clinical studies showed that inhibition of both pathways induces a synergistic effect in several solid 134 
malignancies[23-25]. However, there is a lack of knowledge about the response to dual blockade of 135 
the PI3K/AKT/mTOR and Ras/Raf/MEK pathways in EC. 136 
For the moment, no appropriate preclinical model system exists for EC. Therefore, we established 137 
primary EC cell cultures, as described by Schrauwen et al.[26]. These cell cultures were established 138 
directly from patient tumors and closely resemble the heterogeneity and genomic features of the 139 
primary tumor. They better reflect treatment-response of patients compared to commercial cell 140 
lines[27, 28]. In addition, these cultures can be used for in vivo screening of new treatments, by using 141 
them to establish subcutaneous (s.c.) xenograft models. However, limitations of these models are that 142 
they are not metastatic and the tumors develop in an immunocompromised environment. 143 
There is a lack of knowledge about the effect of blockade of the PI3K/AKT/mTOR and the 144 
Ras/Raf/MEK pathways in EC. Therefore the aim of this study is to determine if targeted therapies 145 
related to these pathways could be a new treatment option for EC. To the best of our knowledge, we 146 
are the first one who used primary endometrioid EC cell cultures to determine the in vitro response to 147 
targeted therapies as single agent treatments and in combination. Three PI3K and/or mTOR inhibitors 148 
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(Temsirolimus, NVP-BKM120, and NVP-BEZ235), and a MEK1/2 inhibitor (AZD6244) were used, 149 
which already showed promising results in clinical trials. In addition, the in vivo response was analyzed 150 
for two s.c. xenograft mouse models treated with NVP-BEZ235. 151 
 152 
Materials and methods 153 
 154 
Establishment of primary endometrial carcinoma cell cultures 155 
Establishment of primary endometrial carcinoma cell cultures is described by Schrauwen et al.[26]. 156 
Briefly, biopsies were collected from chemotherapy-naïve patients undergoing surgery for EC at the 157 
Division of Gynecologic Oncology, University Hospitals Leuven. Tissues were fresh-frozen, formalin-158 
fixed, or used for cell culture. For cell culture, tissues were minced and digested with collagenase type 159 
IV (1 mg/ml; Roche, Mannheim, Germany) in RPMI 1640 medium with Pencillin/Streptomycin, 160 
Fungizone and DNAse I (0.1 mg/ml; Roche, Mannheim, Germany) for 3h at 37°C. Red blood cells 161 
were lysed using Ammonium Chloride (Stem Cell Technologies, Vancouver, Canada). Single cells 162 
were cultured in culture medium, comprising RPMI 1640 medium, 20% Fetal Bovine Serum (FBS), 2 163 
mM L-Glutamine, 100 U/ml Pencillin/Streptomycin, 1 µg/ml Fungizone, and 10 µg/ml gentamycin (all 164 
from Life Technologies, Paisley, UK). Mesenchymal cells were removed using mouse anti-human 165 
CD90 antibody (Clone AS02; Dianova, Hamburg, Germany) and Mouse Pan IgG Dynabeads (Life 166 
Technologies, Oslo, Norway). All cells were cultured in a humidified atmosphere containing 5% CO2. 167 
Cells were routinely monitored for mycoplasma. The study was approved by the local ethical 168 
committees in accordance with the principles of the Declaration of Helsinki and all patients gave their 169 
written informed consent. 170 
 171 
DNA extraction and somatic mutation profiling 172 
As described by Schrauwen et al.[26], the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany) 173 
was used to extract DNA from EC cell cultures, according to the manufacturer’s instructions. Hotspot 174 
mutation profiling was performed of the established EC cell cultures. Selected mutations in KRAS, 175 
PIK3CA, MSH6, TP53, NRAS, BRAF, PTEN and CTNNB1 were determined, based on the COSMIC 176 
database.  177 
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In addition, microsatellite instable (MSI) status of primary EC cell cultures was determined. Briefly, 178 
Sequenom Massarray profiling was used to analyze 59 mononucleotide homopolymers for single 179 
nucleotide insertions or deletions. Cell cultures were determined as MSI if positive for 8 or more 180 
insertions or deletions, and microsatellite stable (MSS) if positive for less than 8 markers. 181 
 182 
Cell viability assay 183 
Cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT) dye 184 
reduction method. Cells were seeded in culture medium containing 10% FBS at a concentration of 185 
5.000 cells/well (n=4) in 96-well plates. After 8h, the medium was replaced by 1% FBS culture 186 
medium. Twenty-four hours after seeding, cells were treated with NVP-BEZ235 (PI3K/mTOR inhibitor), 187 
Temsirolimus (mTOR inhibitor), NVP-BKM120 (PI3K inhibitor), or AZD6244 (MEK1/2 inhibitor) (all 188 
compounds: 0-100 μM, n=4) (all from Selleck Chemicals, Munich, Germany). Cell viability was 189 
determined at 24h, 48h, and 72h, by adding of 40 μl of MTT solution (2.5 mg/ml; Sigma-Aldrich, St. 190 
Louis, USA) to each well and further incubation for 2h. The medium was removed, and the blue 191 
crystals were dissolved in 120 μl 83% dimethyl sulfoxide/17% Sorenson’s glycine buffer. The 192 
absorbance was measured with a microplate reader at 540 nm wavelength. Cell growth was reported 193 
as the percentage of absorbance relative to untreated controls. Each experiment was performed 3 194 
times in triplicate. 195 
Based on these results, the IC50 values of the compounds were calculated for each cell culture at 72h 196 
using CompuSyn. software (Biosoft, Cambridge, UK). 197 
For the analysis of multiple drug treatments, combination index (CI) was calculated according to the 198 
Chou-Talalay method, using a fixed dose ratio[29]. Cells were treated with 0.25x, 0.5x, 1x, 2x, and 4x 199 
their respective IC50’s of the compounds for 72h. Cell viability was measured using the MTT assay and 200 
CI was calculated using CompuSyn. Software (Biosoft, Cambridge, UK). In this analysis, synergy was 201 
defined as CI values lower than 1.0, antagonism as CI values higher than 1.0 and additivity as CI 202 
values equal to 1.0. 203 
. 204 
Cell cycle and apoptosis assay  205 
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For cell cycle and apoptosis assays, cells were seeded in 6-well plates (1.5x10
5
 cells/well, n=1) and 206 
treated for 24h and 48h. Cells were treated with NVP-BEZ235, AZD6244, or the combination of both 207 
compounds. The range of concentrations used was based on calculated IC50 values. 208 
To analyze the cell cycle, cells were fixed with ice-cold 70% ethanol and stained with propidium iode 209 
(PI)/RNase A staining buffer, containing 10 μg PI/ml PBS (Sigma-Aldrich, St. Louis, USA) and 20 μg 210 
RNase A/ml PBS (Sigma-Aldrich, St. Louis, USA). 211 
Apoptosis was determined by double staining with FITC-conjugated Annexin V and PI according to the 212 
manufacturer’s instructions (BD Pharmingen
TM
, Erembodegem, Belgium). 213 
Cell cycle distribution and the percentage of apoptotic cells were analyzed using a flow cytometer 214 
(Becton Dickinson, San Jose, USA) and FlowJo 7.6.5 software (Tree Star Inc., Ashland, USA). 215 
Experiments were repeated twice. 216 
 217 
In vivo evaluation of the efficacy of targeted treatment 218 
Cell-derived xenograft models were established by subcutaneous (s.c.) injection of 5x10
6
 cells in 200 219 
μl PBS per mouse. Mice were treated with either vehicle (10% NMP/90% PEG) (both from Sigma-220 
Aldrich, St. Louis, USA), NVP-BEZ325 (40 mg/kg; daily, p.o.) or carboplatin (50 mg/kg, 1x/week, i.p.) 221 
(Hospira, Antwerp, Belgium) (n=7 per group) for 21 days. Control animals received the equivalent 222 
volume of vehicle. Mice were weighed every week and evaluated for adverse effects. Tumor size was 223 
measured 2x/week with a caliper and the tumor volume was calculated using the following formula: V 224 
= L x W
2
 x (π/6) (V, volume; L, length; W, width). Mice were scarified 1h after last dose. Harvested 225 
tumors were weighed, and fragments were fresh-frozen, or formal-fixed and paraffin-embedded for 226 
further analyses. 227 
 228 
Western blotting 229 
Total protein lysates were obtained from single cell suspensions and tumor tissues post-treatment. 230 
Cells were seeded in 10% FBS culture medium in 100 mm
2
 plates (500.000 cells/plate, n=2). After 8h, 231 
medium was replaced by 1% FBS culture medium. Twenty-four hours after seeding, cells were treated 232 
with either NVP-BEZ235 or AZD6244 or both. The range of concentrations used was based on the 233 
IC50 values. Total protein lysates were prepared from single cell suspensions at 6h and 24h after 234 
treatment-initiation and from tumor tissues using the mammalian cell lysis MCL1 kit (Sigma-Aldrich, St. 235 
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Louis, USA) according to the manufacturer’s instructions. The Pierce BCA protein assay kit (Thermo 236 
Scientific, Waltham, USA) was used to determine protein concentrations. Equal amounts of protein 237 
were run on any kD Mini Protein TGX gel (Bio-Rad, Hercules, USA) and transferred to a 238 
polyvinylidene difluoride membrane (Bio-Rad, Hercules, USA). Next, the membranes were probed with 239 
primary and secondary antibodies. The following primary antibodies were used: AKT, p-AKT
(Ser473)
, S6, 240 
p-S6
(Ser235/Ser236)
, ERK1/2, p-ERK1/2
(Thr202/Tyr204)
 (all at 1/1000), and β-actin (1/2500)(all from Cell 241 
Signaling Technologies, Danvers, USA). Anti-rabbit or -mouse horseradish peroxidase-conjugated 242 
antibodies (Jackson ImmunoResearch, West Grove, USA) were used as secondary antibody. The 243 
enhanced chemiluminescence system (Thermo Scientific, Waltham, USA) and FUJI mini-LAS 4000-244 
plus imaging system (GE Healthcare, Diegem, Belgium) were used to visualize protein expression. 245 
 246 
Statistics 247 
Results are shown as mean ± standard error of mean (SEM). Two-way ANOVA was performed 248 
followed by Bonferroni posttest to determine significant differences between treatment groups with 249 
regard to in vitro cell viability, cell cycle status, and apoptosis induction. One-way ANOVA was 250 
performed for repeated measurements followed by a Tukey’s multiple comparison test to analyze 251 
differences in therapy response over time between treatment groups in vivo. In addition, one-way 252 
ANOVA followed by Tukey’s multiple comparison test was performed to assess differences in tumor 253 
weight between treatment groups. Analyses were performed using GraphPad Prism 5 software 254 
(GraphPad Inc., La Jolla, USA). P-values of p<0.05 were considered to be statistically significant. 255 
 256 
Results 257 
 258 
Single treatment of NVP-BEZ235 and AZD6244 reduced cell viability 259 
We used three primary EC cell cultures as described by Schrauwen et al.[26]. The histologic and 260 
genetic characteristics are described in table 1.  261 
Since these cell cultures showed mutations in the PI3K/AKT/mTOR and Ras/Raf/MEK pathways, we 262 
selected compounds which have an inhibitory effect on proteins involved in these pathways and are 263 
already in clinical trials. For inhibition of the PI3K/AKT/mTOR pathway, we selected NVP-BEZ235 264 
(pan-PI3K/mTOR inhibitor), Temsirolimus (mTORC1 inhibitor), and NVP-BKM120 (PI3K inhibitor). For 265 
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inhibition of the Ras/Raf/MEK pathway we used AZD6244 (MEK1/2 inhibitor). First, we determined the 266 
most potent PI3K/AKT/mTOR pathway inhibitor by treating the three cell cultures with the different 267 
PI3K/AKT/mTOR pathway inhibitors for 72h (all compounds 0-100 μM). NVP-BEZ235 was the only 268 
inhibitor that decreased cell viability in a dose- and time-dependent manner for all 3 cell cultures 269 
(Figure 1). AZD6244 induced a significant reduction of cell viability for all 3 cell cultures at the highest 270 
concentration at 72h (Figure 1). The cell cultures were less sensitive for this compound compared to 271 
NVP-BEZ235 (Table 1). No correlation between mutation profile and response to targeted therapy was 272 
demonstrated. 273 
 274 
Combination treatment of NVP-BEZ235 and AZD6244 showed a synergistic inhibitory effect on cell 275 
viability 276 
We investigated potential synergistic effects of inhibiting both the PI3K/AKT/mTOR and the 277 
Ras/Raf/MEK pathways, by treating with NVP-BEZ235 and AZD6244. The anti-proliferative effect of 278 
this combination was measured in all 3 cell cultures by calculating the CI. The 3 cell cultures were 279 
treated with both NVP-BEZ235 and AZD6244 at 0.25x, 0.5x, 1x, 2x and 4x their respective IC50’s for 280 
72h. For all cell cultures, a synergistic effect was determined by combination of 1x of their respective 281 
IC50’s of each compound, NPV-BEZ235 and AZD6244 (Supplementary file 1). 282 
 283 
NVP-BEZ235 and AZD6244 induced cell cycle arrest 284 
We investigated the effect of NVP-BEZ325 and AZD6244 as single treatments and in combination on 285 
cell cycle arrest for 48h. Since combination treatment with 1x IC50 values of NVP-BEZ235 and 286 
AZD6244 showed a synergistic effect on the cell viability of all cell cultures, the cell cultures were 287 
treated with the respective IC50 values of each compound (Table 1). As shown in figure 2A, at 24h no 288 
cell cycle arrest was induced for all cell cultures. However, only for 2 out of 3 cell cultures, PC-EM001 289 
and PC-EM002, a significant effect on the cell population was determined at 48h. For PC-EM001, 290 
NVP-BEZ235 reduced the number of cells of the S phase compared to control (p<0.05). PC-EM002 291 
showed an increased percentage of the population in the G1 phase of cells treated with NVP-BEZ235 292 
or AZD6244 compared to control (p<0.05 vs p<0.01). In addition, AZD6244 reduced significantly the 293 
number of cells in the S phase compared to control (p<0.05).Combination treatment showed no 294 
enhanced effect compared to single treatment or control (Figure 2B).  295 
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 296 
NVP-BEZ235 and AZD6244 induced apoptosis 297 
We analyzed apoptosis induction by NVP-BEZ235 and AZD6244 as single treatments and in 298 
combination. Early apoptosis was induced in only 2 cell cultures, PC-EM002 and PC-EM004, by single 299 
and combination treatment after 24h (Figure 3A). Also here, cells were treated with the respective 1x 300 
IC50 values of NVP-BEZ235 and AZD6244 as single treatment or combined (Table 1). 301 
PC-EM004 showed an increase in apoptosis, only for the combination treatment, compared to control 302 
(p<0.01) and compared to single treatment of AZD6244 (p<0.05). After 48h of treatment, AZD6244 303 
also induced apoptosis (p<0.05). In contrast, PC-EM002 showed a significant increase in early 304 
apoptosis for both NVP-BEZ235 and AZD6244, as single treatments compared to control (p<0.05 vs 305 
p<0.01) after 24h. Moreover, combination treatment showed a significant increase in apoptosis 306 
compared to control (p<0.001), NVP-BEZ235 (p<0.001), and AZD6244 (p<0.001) as single 307 
treatments. Late apoptosis was induced by combination treatment. After 48h, the same effects were 308 
observed. Interestingly, for PC-EM002 a higher percentage of cells was present in the apoptosis 309 
phase, compared to 24h. In contrast, NVP-BEZ235 induced no apoptosis in PC-EM004 at 48h. We 310 
therefore conclude that both NVP-BEZ235 and AZD6244 induce apoptosis. Moreover, for PC-EM002 311 
and PC-EM004 a synergistic effect was found for combination treatment (Figure 3B).  312 
 313 
NVP-BEZ235 and AZD6244 reduced phosphorylation of proteins related to the PI3K/AKT/mTOR and 314 
Ras/Raf/MEK pathway 315 
To evaluate the short and long term effects of NVP-BEZ235 and AZD6244 on PI3K/AKT/mTOR 316 
signaling and Ras/Raf/MEK signaling, the phosphorylation status of AKT, S6, and ERK were analyzed. 317 
As shown in figure 4, the total protein expression of AKT, S6, and ERK remained unchanged after 318 
treatment with NVP-BEZ235 and AZD6244 for all cell cultures. The primary cell cultures were treated 319 
with the respective IC50 values of related compound (Table 1). PC-EM001 cells were treated with a low 320 
concentration of NVP-BEZ235 (1.8E
-4
µM). This compound showed no difference in phosphorylation of 321 
AKT and S6. In contrast, cells treated with AZD6244 alone or in combination with NVP-BEZ235 had 322 
decreased levels of p-S6 and p-ERK1/2. In PC-EM002 and PC-EM004 cultures, cells were treated 323 
with 0.20µM and 2.09µM NVP-BEZ235, respectively. NVP-BEZ235 decreased p-AKT and p-S6 levels, 324 
whereas AZD6244 induced dephosphorylation of p-S6 and p-ERK1/2. Combination treatment with 325 
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NVP-BEZ235 and AZD6244 inhibited the phoshorylation of p-AKT, p-S6 and p-ERK1/2 for both cell 326 
cultures. Therefore, the effect of NVP-BEZ235 and AZD6244 on the PI3K/AKT/mTOR and 327 
Ras/Raf/MEK pathways seems to be related to the concentration used rather than the mutation profile 328 
of the cell cultures. 329 
 330 
Effect of NVP-BEZ235 on tumor growth in nude mice xenografts 331 
Lastly, we evaluated the effect of NVP-BEZ235 on tumor growth in vivo. This compound was used 332 
since it was the most potent compound in vitro. We established 2 primary s.c. xenograft mouse 333 
models generated from PC-EM002 and PC-EM004 cell cultures, since PC-EM002 cells harbored a 334 
PI3KCA mutation and the PC-EM004 cells the wild-type genes. We treated the mice with NVP-335 
BEZ235, carboplatin (a chemotherapeutic), or vehicle. For both models, NVP-BEZ235 and carboplatin 336 
significantly reduced tumor growth compared to the placebo-treated group. Interestingly, PC-EM004 337 
mice treated with NVP-BEZ235 showed a greater reduction of tumor growth compared to PC-EM002 338 
mice. No difference was determined between the growth-inhibitory effect of NVP-BEZ235 and 339 
carboplatin (Figure 5A). This was confirmed by the wet tumor weight at sacrifice (Figure 5B).  340 
Protein expression in the tumor tissue was investigated by Western Blot. For both models, no effect on 341 
phosphorylation of AKT was determined. In contrast, dephosphorylation of S6 was shown for NVP- 342 
BEZ235 treated mice of both xenograft models and for PC-EM004 mice treated with carboplatin. No 343 
difference in protein expression of AKT, S6, and β-actin was determined all mice (Figure 5C). 344 
 345 
Discussion 346 
 347 
To our knowledge, this is the first study using primary in vitro and in vivo EC models to test the 348 
following targeted therapies: Temsirolimus, NVP-BKM120, NVP-BEZ235 and AZD6244. Our results 349 
suggest a synergistic antitumor effect of NVP-BEZ235 and AZD6244 in primary endometrioid EC cell 350 
cultures, with regard to cell viability and apoptosis, possibly. Interestingly, our results also suggest that 351 
the sensitivity of primary endometrioid EC cell cultures towards either PI3K/mTOR or MEK inhibitors is 352 
independent of mutated genes involved in related pathways. In addition, NVP-BEZ235 was the most 353 
potent inhibitor of the PI3K/AKT/mTOR pathway. In vivo, NVP-BEZ235 reduced tumor growth in mice 354 
harboring tumors with different mutation profiles.  355 
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Treatment options for advanced and recurrent EC are limited. Therefore, new therapies are 356 
necessary. Targeted therapy shows promising response in clinical trials. Therefore, targeted therapies 357 
against the PI3K/AKT/mTOR and Ras/Raf/MEK pathways are an interested new treatment strategy for 358 
EC, especially by blockade of both pathways to prevent compensatory feedback loops. 359 
In this study we used primary preclinical models. Primary cell cultures better represent the histological 360 
and genetic heterogeneity of the primary tumor more compared to commercial cell lines[27, 28]. 361 
Therefore, our results better reflect the response of patients on these treatments compared to models 362 
based on immortalized cell lines. 363 
We showed that dual inhibition of the PI3K/AKT/mTOR pathway, by blocking PI3K and mTOR with 364 
NVP-BEZ235 is more effective compared to inhibition of only PI3K or mTORC1. These results are in 365 
accordance with the results of Shoji et al. and Oishi et al., who used commercial EC cell lines and 366 
ovarian clear cell carcinoma cell lines, respectively[17, 30]. In hepatocellular carcinoma, however, 367 
Kirstein et al. indicated that NVP-BKM120 has a higher antitumor activity compared to RAD001 368 
(mTORC1 inhibitor) and NVP-BEZ235[31].  369 
MSI tumors show high frequent differentiating mutation profiles and therefore it is difficult to determine 370 
driver and passenger mutations. Our results are interesting since all primary cell cultures were 371 
sensitive to NVP-BEZ235 and AZD6244 and these compounds induced a synergistic effect with 372 
regard to cell viability and apoptosis, despite the MSI status. Low concentrations of NVP-BEZ235 373 
(1.8E
-4
µM) did not affect phosphorylation of AKT and S6. In contrast, high concentrations (0.20µM and 374 
2.09µM) reduced p-AKT and p-S6 levels. Therefore, induced effects seem related to the concentration 375 
ranges used rather than the IC50 values. Moreover, also in vivo no correlation was determined 376 
between the mutation profile of tumors and response to NVP-BEZ235. This is in accordance with 377 
previous results for other type of cancers, in which the presence of KRAS gene mutation was not 378 
predictive of sensitivity to MEK or PI3K inhibitors[32-34]. In addition, the response of EC xenografts to 379 
NVP-BKM120 was independent of the presence of a PIK3CA gene mutation[12]. However, we have to 380 
take into account that we used a limited number of primary endometrioid EC cell cultures. To 381 
investigate the in vitro and in vivo responses on combination of targeted therapies, further studies 382 
should include a larger panel of type I and type II EC, including MSS tumors. In addition, the use of 383 
MSS tumors could be useful to determine biomarkers able to predict the response to targeted 384 
therapies. 385 
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In vitro, NVP-BEZ235 was a more potent compound on PC-EM002 cells than on PC-EM004 cells. In 386 
contrast, in vivo results showed a higher tumor growth reduction for mice bearing PC-EM004 tumors 387 
compared to PC-EM002 mice. Other studies demonstrated also this phenomenon that in vitro 388 
sensitivity to mTORC1 inhibitors does not correlate with in vivo sensitivity[35, 36]. Fuereder et al. 389 
showed that in vivo efficacy of NVP-BEZ235 is not correlated with PI3K/mTOR target regulation, 390 
hotspot mutations in PIK3CA, Ras or BRAF in gastric tumor xenograf models, based on commercial 391 
cell lines[35].  392 
In vivo, NVP-BEZ235 showed the same effect on tumor growth inhibition as carboplatin. It is shown 393 
that NVP-BEZ235 synergizes with chemotherapy in vitro and in vivo for several cancers[37, 38]. In 394 
addition, combination of dual PI3K/mTOR inhibitors with radiotherapy can improve radiosensitivity in 395 
radioresistant prostate cancer cells[39]. Therefore, combination treatment of (neo)adjuvant therapy 396 
and targeted therapy for advanced and recurrent EC could be an interesting strategy, especially for 397 
patients harboring a chemo- or radioresistant tumor. Further comprehensive studies should be 398 
performed to test the safety and efficacy in vitro and in vivo of these treatments before clinical 399 
application. 400 
Although the present study has several limitations such as the small number of cell cultures tested in 401 
vitro and in vivo, it demonstrated a synergistic interaction between NVP-BEZ235 and AZD6244 in 402 
primary endometrioid EC cells in vitro. In addition, NVP-BEZ235 showed the same anti-proliferative 403 
effects as carboplatin in vivo. Therefore, it will be interesting to determine the synergistic effect of 404 
targeted therapies and currently used therapies. Remarkably, the antitumor effects of single and 405 
combination treatment of targeted therapies in vitro and in vivo were independent of mutations related 406 
to the PI3K/AKT/mTOR and Ras/Raf/MEK pathway. Moreover, they showed anticancer effects in MSI 407 
defined tumors.  Altogether, targeted therapies against PI3K and/or mTOR seem a promising 408 
treatment strategy for EC. 409 
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Figures and legends 536 
 537 
Table 1. IC50 values of three primary endometrioid EC cell cultures for PI3K and/or mTOR 538 
inhibitors and a MEK inhibitor (AZD6244) at 72h. 539 
 540 
Figure 1. The effect of NVP-BEZ235, Temsirolimus, NVP-BKM120 and AZD6244 on cell viability 541 
in primary endometrial carcinoma cell cultures. Dose response curves of NVP-BEZ235, 542 
Temsirolimus, NVP-BKM120, and AZD6244 for all primary cell cultures are shown. All cell cultures 543 
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were treated with increasing doses of the 4 compounds (0-100 μM) (n=4 wells per concentration) for 544 
72h. Changes in cell proliferation were examined by MTT assay. Each data point represents the mean 545 
± SEM of triplicate experiments. * p<0.05, ** p<0.01, *** p<0.001 compared to control, two-way 546 
ANOVA with Bonferroni post hoc test. 547 
 548 
Figure 2. The induction of cell cycle arrest by NVP-BEZ235 and AZD6244 on in primary 549 
endometrial carcinoma cell cultures. Three primary EC cell cultures were treated with NVP-550 
BEZ235, AZD6244 as single or combination treatment. Cell cultures were treated with the respective 551 
IC50 values of NVP-BEZ235 and AZD6244. Cell cycle distribution was determined at 24h, and 48h. A) 552 
At 24h no cell cycle arrest was induced for all cell cultures. B) After 48h, NVP-BEZ235 and AZD6244 553 
increased the population of cells in the S phase for PC-EM001 and PC-EM002. In addition, an 554 
increased percentage of cell in G1 phase of PC-EM002 was determined for NVP-BEZ235 and 555 
AZD6244 treatment. Data represent the mean ± SEM of duplicate experiments after 48h of treatment. 556 
* p<0.05, ** p<0.01, *** p<0.001 compared to each treatment group, two-way ANOVA with Bonferroni 557 
post hoc test. 558 
 559 
Figure 3. The effect of NVP-BEZ235 and AZD6244 on early and late apoptosis in primary 560 
endometrial carcinoma cell cultures. Three primary EC cell cultures were treated with NVP-BEZ235 561 
combined with AZD6244 or as single treatments. Cell cultures were treated with the respective IC50 562 
values of NVP-BEZ235 and AZD6244. Induction of apoptosis was determined at 24h, and 48h. A) For 563 
two cell cultures, PC-EM002 and PC-EM004, early apoptosis was induced at 24h. PC-EM002 also 564 
showed late apoptosis in response to combination treatment at 24h. B) After 48h, an increased 565 
apoptosis was induced in PC-EM002 cells. Data represent the mean ± SEM of duplicate experiments 566 
after 24h and 48h of treatment. * p<0.05, ** p<0.01, *** p<0.001 compared to each treatment group, 567 
two-way ANOVA with Bonferroni post hoc test. 568 
 569 
Figure 4. The influence of NVP-BEZ235 and AZD6244 on activation of cell signaling pathways. 570 
Cells were incubated with NVP-BEZ235 and/or AZD6244 for 6h and 24h. Cell cultures were treated 571 
with the respective IC50 values of NVP-BEZ235 and AZD6244. Phosphorylation of AKT, S6, and 572 
ERK1/2 was analyzed by Western Blotting. In the PC-EM001 cell culture, only AZD6244 showed an 573 
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effect on phosphorylation of investigated proteins, by dephosphorylation of p-S6
(Ser235/236)
 and p-574 
ERK1/2
(Thr202/Tyr204)
. In PC-EM002 and PC-EM004 cultures, NVP-BEZ235 reduced p-AKT
(Ser473)
 and p-575 
S6
(Ser235/236)
 levels and AZD6244 decreased p-S6
(Ser235/236)
 and p-ERK
(Thr202/Tyr204)
 levels. Combination 576 
treatment showed dephosphorylation of all 3 proteins for both cell cultures. Effects were determined 577 
for at least 24h. 578 
 579 
Figure 5. The effect of NVP-BEZ235 on tumor growth in vivo. PC-EM002 and PC-EM004 bearing 580 
mice were treated with vehicle (10% NMP/90% PEG), NVP-BEZ235 (40 mg/kg; daily, p.o,), or 581 
carboplatin (50 mg/kg, 1x/week, i.p.) (n=7). A) NVP-BEZ235 reduced tumor growth for PC-EM002 and 582 
even stabilized tumor growth for PC-EM004. The effect of targeted therapy was comparable to 583 
chemotherapy. One-way ANOVA for repeated measurements followed by Tukey’s multiple 584 
comparison test was performed. B) Wet tumor weights were significantly different between mice 585 
treated with a compound and mice treated with placebo. One-way ANOVA followed by Tukey’s 586 
multiple comparison test was performed. C) For both xenograft models a reduction of p-S6 was 587 
demonstrated for tumors of mice treated with NVP-BEZ235.  588 
Results are presented as mean ± SEM. ** p<0.01, *** p<0.001 compared to placebo group. 589 
 590 
S1. Overview combination index of primary endometrioid endometrial carcinoma cell cultures 591 
treated with a combination of NPV-BEZ235 and AZD6244 for 72h. Combination index: Synergistic 592 
effect is indicated in blue and antagonistic effect is indicated in orange. 593 
 ID cell culture Histopathology Grade 
FIGO Stage 
(2009) 
Mutation profile 
NVP-BEZ235 
(μM) 
AZD6244 
(μM) 
PC-EM001 Endometrioid 2 II KRAS_G35 ACT (GT) 1.80E-4 27.00 
PC-EM002 
Dedifferentiated 
endometrioid 
3 II 
PIK3CA_277T (TC) 
0.20 79.70 
PTEN_697 (CT) 
PC-EM004 
Mixed 
endometrioid/serous 
3 IA / 2.09 41.55 
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1.80E-4 1.21 0.56 0.45 0.43 0.32 
0.90E-4 2.18 1.09 0.41 0.47 0.23 
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NVP-BEZ235 (μM) 
0.80 0.10 0.19 0.36 0.67 1.34 
0.40 0.11 0.19 0.35 0.66 1.35 
0.20 0.10 0.19 0.35 0.67 1.37 
0.10 0.11 0.19 0.36 0.67 1.36 
0.05 0.11 0.19 0.36 0.68 1.36 
19.93 39.85 79.70 159.40 318.80 AZD6244 (μM) 
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NVP-BEZ235 (μM) 
8.40 0.06 0.10 0.17 0.26 0.46 
4.20 0.07 0.11 0.17 0.25 0.47 
2.10 0.08 0.12 0.19 0.29 0.47 
1.05 0.07 0.13 0.22 0.29 0.48 
0.53 0.07 0.12 0.22 0.31 0.47 
10.39 20.78 41.55 83.10 166.20 AZD6244 (μM) 
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